首页> 外文OA文献 >Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

【2h】

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

机译：曲妥珠单抗新辅助治疗后根据HER-2扩增水平的病理学完全缓解和生存

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Guiu, S; Gauthier, M; Coudert, B; Bonnetain, F; Favier, L; Ladoire, S; Tixier, H; Guiu, B; Penault-Llorca, F; Ettore, F; Fumoleau, P; Arnould, L;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种 {"code":"en","name":"English","id":9}
中图分类

相似文献

外文文献
中文文献
专利

1. Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer [J] . S Guiu, M Gauthier, B Coudert, British Journal of Cancer . 2010,第9期

机译：基于曲妥珠单抗的乳腺癌新辅助治疗后HER-2扩增水平的病理学完全缓解和生存
2. Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy [J] . Liu Shiwei, Duan Xuening, Xu Ling, Tumour biology : . 2016,第4期

机译：核Gli1表达与曲妥珠单抗新辅助疗法治疗的HER2阳性乳腺癌的病理完全缓解和无事件生存相关
3. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer [J] . Choi Jin Hyuk, Jeon Chang Wan, Kim Young Ok, Medicine. . 2020,第46期

机译：对Neoadjuvant Trastuzumab和Pertuzumab治疗的病理完全反应与Her2扩增乳腺癌中的人表皮生长因子受体2（HER2）扩增水平有关
4. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Deep Learning with Integrative Imaging, Molecular and Demographic Data [C] . Hongyi Duanmu, Pauline Boning Huang, Srinidhi Brahmavar, International Conference on Medical Image Computing and Computer-Assisted Intervention . 2020

机译：利用综合成像，分子和人口统计数据预测对乳腺癌新辅助化疗的病理完全反应
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer [O] . S Guiu, M Gauthier, B Coudert, 2010

机译：曲妥珠单抗新辅助治疗后根据HER-2扩增水平的病理学完全缓解和生存
7. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy [O] . Patrizia Vici, Marcella Mottolese, Laura Pizzuti, 2014

机译：Hippo Cransducer Taz作为HER2阳性乳腺癌患者的病理完全反应的生物标志物，该乳腺癌患者治疗了曲妥珠单抗的新辅助治疗

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅